NGENLA™, a long-acting human growth hormone (hGH) molecule, is a once-weekly injectable, created using recombinant technology, for the treatment of children and adolescents with a growth hormone deficiency (GHD). The molecule consists of the natural peptide sequence of native growth hormone and the 28 amino acids of the CTP. This molecule, as compared to current GH replacement therapies, is intended to reduce the injection frequency from a daily to once a week in children and adolescents with GHD.
NGENLA™ Received Marketing Authorization for the treatment of Pediatric Growth Hormone Deficiency in the U.S., the European Union, UK, Canada, Australia, South Korea, Japan, Taiwan, India and Brazil.